Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Posted by Logan Wallace on Mar 28th, 2025

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 48,500 shares, an increase of 889.8% from the February 28th total of 4,900 shares. Approximately 3.0% of the company’s stock are sold short. Based on an average daily trading volume, of 820,700 shares, the days-to-cover ratio is presently 0.1 days.

Galmed Pharmaceuticals Price Performance

Shares of NASDAQ GLMD opened at $1.68 on Friday. Galmed Pharmaceuticals has a one year low of $1.65 and a one year high of $23.80. The business’s 50-day moving average price is $2.40 and its two-hundred day moving average price is $3.38. The company has a market capitalization of $1.08 million, a P/E ratio of -0.10 and a beta of 0.72.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research note on Friday. They set a “sell” rating for the company.

Get Our Latest Report on Galmed Pharmaceuticals

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.